Skip to main content
SpringerLink
Log in

Issues in Long-Term Management of Adults with Growth Hormone Deficiency

  • Chapter
  • First Online:
Growth Hormone Related Diseases and Therapy

Part of the book series: Contemporary Endocrinology ((COE))

Abstract

The first clinical trials of recombinant growth hormone (GH) replacement in GH-deficient (GHD) adults were carried out in the 1980s. Since some of the original participants in these trials have continued to the present day on GH replacement, there are now patients who have been treated with GH in adult life for more than 20 years and many more who have been treated for more than a decade. It is timely to consider the long-term effects of GH replacement both from the point of view of efficacy and safety. Assessment of long-term effects of GH replacement is difficult due to lack of placebo-controlled data, but insights can be gained from a number of sources including follow-up studies of early trials, cohort studies from individual centres, and surveillance studies undertaken by pharmaceutical companies.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Carroll PV, Christ ER, Bengtsson BA, et al. Growth hormone deficiency in adulthood and the effects of growth hormone replacement: a review. Growth Hormone Research Society Scientific Committee. J Clin Endocrinol Metab. 1998;83(2):382–95.

    Article  PubMed  CAS  Google Scholar 

  2. de Boer H, Blok G-J, van der Veen EA. Clinical aspects of growth hormone deficiency in adults. Endocr Rev. 1995;16:63–86.

    Article  PubMed  Google Scholar 

  3. Gibney J, Healy ML, Sonksen PH. The growth hormone/insulin-like growth factor-I axis in exercise and sport. Endocr Rev. 2007;28(6):603–24.

    Article  PubMed  CAS  Google Scholar 

  4. Drake WM, Howell SJ, Monson JP, Shalet SM. Optimizing GH therapy in adults and children. Endocr Rev. 2001;22(4):425–50.

    Article  PubMed  CAS  Google Scholar 

  5. Ohlsson C, Bengtsson BA, Isaksson OG, Andreassen TT, Slootweg MC. Growth hormone and bone. Endocr Rev. 1998;19(1):55–79.

    Article  PubMed  CAS  Google Scholar 

  6. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Shalet SM, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endo Metab. 2006;91(5):1621–34.

    Article  CAS  Google Scholar 

  7. Sherlock M, Ayuk J, Tomlinson JW, et al. Mortality in patients with pituitary disease. Endocr Rev. 2010;31(3):301–42.

    Article  PubMed  Google Scholar 

  8. Burman P, Broman JE, Hetta J, et al. Quality of life in adults with growth hormone (GH) deficiency: response to treatment with recombinant human GH in a placebo-controlled 21-month trial. J Clin Endocrinol Metab. 1995;80(12):3585–90.

    Article  PubMed  CAS  Google Scholar 

  9. Wallymahmed ME, Foy P, Shaw D, Hutcheon R, Edwards RH, MacFarlane IA. Quality of life, body composition and muscle strength in adult growth hormone deficiency: the influence of growth hormone replacement therapy for up to 3 years. Clin Endocrinol (Oxf). 1997;47(4):439–46.

    Article  CAS  Google Scholar 

  10. Widdowson WM, Gibney J. The Effect of Growth Hormone Replacement on Exercise Capacity in Patients with GH-deficiency: A Meta-Analysis. J Clin Endocrinol Metab. 2008;93(11):4413–7.

    Article  PubMed  CAS  Google Scholar 

  11. Maison P, Chanson P. Cardiac effects of growth hormone in adults with growth hormone deficiency: a meta-analysis. Circulation. 2003;108(21):2648–52.

    Article  PubMed  CAS  Google Scholar 

  12. Maison P, Griffin S, Nicoue-Beglah M, Haddad N, Balkau B, Chanson P. Impact of growth hormone (GH) treatment on cardiovascular risk factors in GH-deficient adults: a metaanalysis of blinded, randomized, placebo-controlled trials. J Clin Endocrinol Metab. 2004;89(5):2192–9.

    Article  PubMed  CAS  Google Scholar 

  13. Widdowson WM, Gibney J. The effect of growth hormone (GH) replacement on muscle strength in patients with GH-deficiency: a meta-analysis. Clin Endocrinol (Oxf). 2010;72(6):787–92.

    Article  CAS  Google Scholar 

  14. Arwert LI, Deijen JB, Witlox J, Drent ML. The influence of growth hormone (GH) substitution on patient-reported outcomes and cognitive functions in GH-deficient patients: a meta-analysis. Growth Horm IGF Res. 2005;15(1):47–54.

    Article  PubMed  CAS  Google Scholar 

  15. Nabarro JD. Acromegaly. Clin Endocrinol (Oxf). 1987;26(4):481–512.

    Article  CAS  Google Scholar 

  16. Takala J, Ruokonen E, Webster NR, et al. Increased mortality associated with growth hormone treatment in critically ill adults. N Engl J Med. 1999;341:785–92.

    Article  PubMed  CAS  Google Scholar 

  17. Swerdlow AJ, Higgins CD, Adlard P, Preece MA. Risk of cancer in patients treated with human pituitary growth hormone in the UK, 1959–85: a cohort study. Lancet. 2002;360:273–7.

    Article  PubMed  CAS  Google Scholar 

  18. Cutfield WS, Wilton P, Bennmarker H, et al. Incidence of diabetes mellitus and impaired glucose tolerance in children and adolescents receiving growth-hormone treatment. Lancet. 2000;355(9204):610–3.

    Article  PubMed  CAS  Google Scholar 

  19. Khandwala HM, McCutcheon IE, Flyvbjerg A, Friend KE. The effects of insulin-like growth factors on tumorigenesis and neoplastic growth. Endocr Rev. 2000;21(3):215–44.

    Article  PubMed  CAS  Google Scholar 

  20. Hoffman DM, O’Sullivan AJ, Freund J, Ho KK. Adults with growth hormone deficiency have abnormal body composition but normal energy metabolism. J Clin Endocrinol Metab. 1995;80(1):72–7.

    Article  PubMed  CAS  Google Scholar 

  21. Bengtsson BA, Eden S, Lonn L, et al. Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab. 1993;76(2):309–17.

    Article  PubMed  CAS  Google Scholar 

  22. Gibney J, Wallace JD, Spinks T, et al. The effects of 10 years of recombinant human growth hormone (GH) in adult GH-deficient patients. J Clin Endocrinol Metab. 1999;84(8):2596–602.

    Article  PubMed  CAS  Google Scholar 

  23. Chrisoulidou A, Beshyah SA, Rutherford O, et al. Effects of 7 years of growth hormone replacement therapy in hypopituitary adults. J Clin Endocrinol Metab. 2000;85(10):3762–9.

    Article  PubMed  CAS  Google Scholar 

  24. Gotherstrom G, Bengtsson BA, Bosaeus I, Johannsson G, Svensson J. A 10-year, prospective study of the metabolic effects of growth hormone replacement in adults. J Clin Endocrinol Metab. 2007;92(4):1442–5.

    Article  PubMed  CAS  Google Scholar 

  25. Svensson J, Fowelin J, Landin K, Bengtsson BA, Johansson JO. Effects of seven years of GH-replacement therapy on insulin sensitivity in GH-deficient adults. J Clin Endocrinol Metab. 2002;87(5):2121–7.

    Article  PubMed  CAS  Google Scholar 

  26. ter Maaten JC, de Boer H, Kamp O, Stuurman L, van der Veen EA. Long-term effects of growth hormone (GH) replacement in men with childhood-onset GH deficiency. J Clin Endocrinol Metab. 1999;84(7):2373–80.

    Article  PubMed  Google Scholar 

  27. Fideleff HL, Boquete HR, Stalldecker G, Giaccio AV, Sobrado PG. Comparative results of a 4-year study on cardiovascular parameters, lipid metabolism, body composition and bone mass between untreated and treated adult growth hormone deficient patients. Growth Horm IGF Res. 2008;18(4):318–24.

    Article  PubMed  CAS  Google Scholar 

  28. Wuster C, Abs R, Bengtsson BA, et al. The influence of growth hormone deficiency, growth hormone replacement therapy, and other aspects of hypopituitarism on fracture rate and bone mineral density. J Bone Miner Res. 2001;16(2):398–405.

    Article  PubMed  CAS  Google Scholar 

  29. Murray RD, Columb B, Adams JE, Shalet SM. Low bone mass is an infrequent feature of the adult growth hormone deficiency syndrome in middle-age adults and the elderly. J Clin Endocrinol Metab. 2004;89:1124–30.

    Article  PubMed  CAS  Google Scholar 

  30. Arwert LI, Roos JC, Lips P, Twisk JW, Manoliu RA, Drent ML. Effects of 10 years of growth hormone (GH) replacement therapy in adult GH-deficient men. Clin Endocrinol (Oxf). 2005;63(3):310–6.

    Article  CAS  Google Scholar 

  31. Gotherstrom G, Svensson J, Koranyi J, et al. A prospective study of 5 years of GH replacement therapy in GH-deficient adults: sustained effects on body composition, bone mass, and metabolic indices. J Clin Endocrinol Metab. 2001;86(10):4657–65.

    Article  PubMed  CAS  Google Scholar 

  32. Biermasz NR, Hamdy NA, Pereira AM, Romijn JA, Roelfsema F. Long-term skeletal effects of recombinant human growth hormone (rhGH) alone and rhGH combined with alendronate in GH-deficient adults: a seven-year follow-up study. Clin Endocrinol (Oxf). 2004;60(5):568–75.

    Article  CAS  Google Scholar 

  33. Woodhouse LJ, Mukherjee A, Shalet SM, Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev. 2006;27(3):287–317.

    Article  PubMed  CAS  Google Scholar 

  34. Johannsson G, Grimby G, Sunnerhagen KS, Bengtsson BA. Two years of growth hormone (GH) treatment increase isometric and isokinetic muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 1997;82(9):2877–84.

    Article  PubMed  CAS  Google Scholar 

  35. Svensson J, Stibrant Sunnerhagen K, Johannsson G. Five years of growth hormone replacement therapy in adults: age- and gender-related changes in isometric and isokinetic muscle strength. J Clin Endocrinol Metab. 2003;88(5):2061–9.

    Article  PubMed  CAS  Google Scholar 

  36. Gotherstrom G, Elbornsson M, Stibrant-Sunnerhagen K, Bengtsson BA, Johannsson G, Svensson J. Ten years of growth hormone (GH) replacement normalizes muscle strength in GH-deficient adults. J Clin Endocrinol Metab. 2009;94(3):809–16.

    Article  PubMed  Google Scholar 

  37. Christ ER, Cummings MH, Lumb PJ, Crook MA, Sonksen PH, Russell-Jones DL. Growth hormone (GH) replacement therapy reduces serum sialic acid concentrations in adults with GH-deficiency: a double-blind placebo- controlled study. Clin Endocrinol (Oxf). 1999;51(2):173–9.

    Article  CAS  Google Scholar 

  38. Johannsson JO, Landin K, Tengborn L, Rosen T, Bengtsson BA. High fibrinogen and plasminogen activator inhibitor activity n growth hormone-deficient adults. Arterioscler Thromb. 1994;14:434–7.

    Article  Google Scholar 

  39. Colao A, Di Somma C, Spiezia S, et al. Growth hormone treatment on atherosclerosis: results of a 5-year open, prospective, controlled study in male patients with severe growth hormone deficiency. J Clin Endocrinol Metab. 2008;93(9):3416–24.

    Article  PubMed  CAS  Google Scholar 

  40. Persson J, Formgren J, Israelsson B, Berglund G. Ultrasound-determined intima-media thickness and atherosclerosis. Direct and indirect validation. Arterioscler Thromb. 1994;14(2):261–4.

    Article  PubMed  CAS  Google Scholar 

  41. Colao A, Di Somma C, Cuocolo A, et al. Does a gender-related effect of growth hormone (GH) replacement exist on cardiovascular risk factors, cardiac morphology, and performance and atherosclerosis? Results of a two-year open, prospective study in young adult men and women with severe GH deficiency. J Clin Endocrinol Metab. 2005;90(9):5146–55.

    Article  PubMed  CAS  Google Scholar 

  42. Thuesen L, Jørgensen JOL, Müller JR, et al. Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults. Clin Endocrinol. 1994;41:615–20.

    Article  CAS  Google Scholar 

  43. Johannsson G, Bengtsson B-Å, Andersson B, Isgaard J, Caidahl K. Long-term cardiovascular effects of growth hormone treatment in GH-deficient adults: preliminary data from a small group of patients. Clin Endocrinol (Oxf). 1996;45:305–14.

    Article  CAS  Google Scholar 

  44. Deijen JB, Arwert LI, Witlox J, Drent ML. Differential effect sizes of growth hormone replacement on Quality of Life, well-being and health status in growth hormone deficient patients: a meta-analysis. Health Qual Life Outcomes. 2005;3:63.

    Article  PubMed  Google Scholar 

  45. Rosilio M, Blum WF, Edwards DJ, et al. Long-term improvement of quality of life during growth hormone (GH) replacement therapy in adults with GH deficiency, as measured by questions on life satisfaction-hypopituitarism (QLS-H). J Clin Endocrinol Metab. 2004;89(4):1684–93.

    Article  PubMed  CAS  Google Scholar 

  46. Koltowska-Haggstrom M, Mattsson AF, Monson JP, et al. Does long-term GH replacement therapy in hypopituitary adults with GH deficiency normalise quality of life? Eur J Endocrinol. 2006;155(1):109–19.

    Article  PubMed  Google Scholar 

  47. Sherlock M, Aragon Alonso A, Reulen RC, et al. Monitoring disease activity using GH and IGF-I in the follow-up of 501 patients with acromegaly. Clin Endocrinol (Oxf). 2009;71(1):74–81.

    Article  CAS  Google Scholar 

  48. Gibney J, Johannsson G. Long-term monitoring of insulin-like growth factor I in adult growth hormone deficiency: a critical appraisal. Horm Res. 2004;62 Suppl 1:66–72.

    Article  PubMed  CAS  Google Scholar 

  49. Beshyah SA, Henderson A, Niththyanathan R, Sharp P, Richmond W, Johnston DG. Metabolic abnormalities in growth hormone deficient adults: II. Carbohydrate tolerance and lipid metabolism. Endocrinol Metab. 1994;1:173–80.

    Google Scholar 

  50. Hew FL, Koschmann M, Christopher M, et al. Insulin resistance in growth hormone-deficient adults: defects in glucose utilization and glycogen synthase activity. J Clin Endocrinol Metab. 1996;81(2):555–64.

    Article  PubMed  CAS  Google Scholar 

  51. Johansson JO, Fowelin J, Landin K, Lager I, Bengtsson BA. Growth hormone-deficient adults are insulin-resistant. Metabolism. 1995;44(9):1126–9.

    Article  PubMed  CAS  Google Scholar 

  52. Attanasio AF, Mo D, Erfurth EM, et al. Prevalence of metabolic syndrome in adult hypopituitary growth hormone (GH)-deficient patients before and after GH replacement. J Clin Endocrinol Metab. 2010;95(1):74–81.

    Article  PubMed  CAS  Google Scholar 

  53. Bell J, Parker KL, Swinford RD, Hoffman AR, Maneatis T, Lippe B. Long-term safety of recombinant human growth hormone in children. J Clin Endocrinol Metab. 2010;95(1):167–77.

    Article  PubMed  CAS  Google Scholar 

  54. Hoffman AR, Kuntze JE, Baptista J, et al. Growth hormone (GH) replacement therapy in adult-onset GH deficiency: effects on body composition in men and women in a double-blind, randomized, placebo-controlled trial. J Clin Endocrinol Metab. 2004;89(5):2048–56.

    Article  PubMed  CAS  Google Scholar 

  55. Holmer H, Svensson J, Rylander L, et al. Nonfatal stroke, cardiac disease, and diabetes mellitus in hypopituitary patients on hormone replacement including growth hormone. J Clin Endocrinol Metab. 2007;92(9):3560–7.

    Article  PubMed  CAS  Google Scholar 

  56. Jogie-Brahim S, Feldman D, Oh Y. Unraveling insulin-like growth factor binding protein-3 actions in human disease. Endocr Rev. 2009;30(5):417–37.

    Article  PubMed  CAS  Google Scholar 

  57. Nilsson B, Gustavasson-Kadaka E, Bengtsson BA, Jonsson B. Pituitary adenomas in Sweden between 1958 and 1991: incidence, survival, and mortality. J Clin Endocrinol Metab. 2000;85(4):1420–5.

    Article  PubMed  CAS  Google Scholar 

  58. Brada M, Rajan B, Traish D, et al. The long-term efficacy of conservative surgery and radiotherapy in the control of pituitary adenomas. Clin Endocrinol (Oxf). 1993;38(6):571–8.

    Article  CAS  Google Scholar 

  59. Hatrick AG, Boghalo P, Bingham JB, Ayres AB, Sonksen PH, Russell-Jones DL. Does GH replacement therapy in adult GH-deficient patients result in recurrence or increase in size of pituitary tumours? Eur J Endocrinol. 2002;146(6):807–11.

    Article  PubMed  CAS  Google Scholar 

  60. Arnold JR, Arnold DF, Marland A, Karavitaki N, Wass JA. GH replacement in patients with non-functioning pituitary adenoma (NFA) treated solely by surgery is not associated with increased risk of tumour recurrence. Clin Endocrinol (Oxf). 2009;70(3):435–8.

    Article  CAS  Google Scholar 

  61. Frajese G, Drake WM, Loureiro RA, et al. Hypothalamo-pituitary surveillance imaging in hypopituitary patients receiving long-term GH replacement therapy. J Clin Endocrinol Metab. 2001;86(11):5172–5.

    Article  PubMed  CAS  Google Scholar 

  62. Abs R, Bengtsson BA, Hernberg-Stahl E, et al. GH replacement in 1034 growth hormone deficient hypopituitary adults: demographic and clinical characteristics, dosing and safety. Clin Endocrinol (Oxf). 1999;50(6):703–13.

    Article  CAS  Google Scholar 

  63. Renehan AG, Zwahlen M, Minder C, O’Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet. 2004;363(9418):1346–53.

    Article  PubMed  CAS  Google Scholar 

  64. Roddam AW, Allen NE, Appleby P, et al. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med. 2008;149(7):461–71, W483–68.

    Google Scholar 

  65. Key TJ, Appleby PN, Reeves GK, Roddam AW. Insulin-like growth factor 1 (IGF1), IGF binding protein 3 (IGFBP3), and breast cancer risk: pooled individual data analysis of 17 prospective studies. Lancet Oncol. 2010;11(6):530–42.

    Article  PubMed  Google Scholar 

  66. Jostel A, Mukherjee A, Hulse PA, Shalet SM. Adult growth hormone replacement therapy and neuroimaging surveillance in brain tumour survivors. Clin Endocrinol (Oxf). 2005;62(6):698–705.

    Article  CAS  Google Scholar 

  67. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002;87(7):3136–41.

    Article  PubMed  CAS  Google Scholar 

  68. Svensson J, Bengtsson BA, Rosen T, Oden A, Johannsson G. Malignant disease and cardiovascular morbidity in hypopituitary adults with or without growth hormone replacement therapy. J Clin Endocrinol Metab. 2004;89(7):3306–12.

    Article  PubMed  CAS  Google Scholar 

  69. Popovic V, Mattsson AF, Gaillard RC, Wilton P, Koltowska-Haggstrom M, Ranke MB. Serum insulin-like growth factor I (IGF-I), IGF-binding proteins 2 and 3, and the risk for development of malignancies in adults with growth hormone (GH) deficiency treated with GH: Data from KIMS (Pfizer International Metabolic Database). J Clin Endocrinol Metab. 2010;95(9):4449–54.

    Article  PubMed  CAS  Google Scholar 

  70. Roubenoff R, Parise H, Payette HA, et al. Cytokines, insulin-like growth factor 1, sarcopenia, and mortality in very old community-dwelling men and women: the Framingham Heart Study. Am J Med. 2003;115(6):429–35.

    Article  PubMed  CAS  Google Scholar 

  71. Friedrich N, Haring R, Nauck M, et al. Mortality and serum insulin-like growth factor (IGF)-I and IGF binding protein 3 concentrations. J Clin Endocrinol Metab. 2009;94(5):1732–9.

    Article  PubMed  CAS  Google Scholar 

  72. Saydah S, Graubard B, Ballard-Barbash R, Berrigan D. Insulin-like growth factors and subsequent risk of mortality in the United States. Am J Epidemiol. 2007;166(5):518–26.

    Article  PubMed  Google Scholar 

  73. Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004;89(1):114–20.

    Article  PubMed  CAS  Google Scholar 

  74. Harrela M, Qiao Q, Koistinen R, et al. High serum insulin-like growth factor binding protein-1 is associated with increased cardiovascular mortality in elderly men. Horm Metab Res. 2002;34(3):144–9.

    Article  PubMed  CAS  Google Scholar 

  75. Ho KK. Consensus guidelines for the diagnosis and treatment of adults with GH deficiency II: a statement of the GH Research Society in association with the European Society for Pediatric Endocrinology, Lawson Wilkins Society, European Society of Endocrinology, Japan Endocrine Society, and Endocrine Society of Australia. Eur J Endocrinol. 2007;157(6):695–700.

    Article  PubMed  CAS  Google Scholar 

  76. Cook DM, Yuen KC, Biller BM, Kemp SF, Vance ML. American Association of Clinical Endocrinologists medical guidelines for clinical practice for growth hormone use in growth hormone-deficient adults and transition patients – 2009 update. Endocr Pract. 2009;15 Suppl 2:1–29.

    PubMed  Google Scholar 

  77. Giavoli C, Libe R, Corbetta S, et al. Effect of recombinant human growth hormone (GH) replacement on the hypothalamic-pituitary-adrenal axis in adult GH-deficient patients. J Clin Endocrinol Metab. 2004;89(11):5397–401.

    Article  PubMed  CAS  Google Scholar 

  78. Porretti S, Giavoli C, Ronchi C, et al. Recombinant human GH replacement therapy and thyroid function in a large group of adult GH-deficient patients: when does L-T(4) therapy become mandatory? J Clin Endocrinol Metab. 2002;87(5):2042–5.

    Article  PubMed  CAS  Google Scholar 

  79. Cook DM, Ludlam WH, Cook MB. Route of estrogen administration helps to determine growth hormone (GH) replacement dose in GH-deficient adults. J Clin Endocrinol Metab. 1999;84(11):3956–60.

    Article  PubMed  CAS  Google Scholar 

  80. Gibney J, Healy ML, Stolinski M, et al. Effect of growth hormone (GH) on glycerol and free fatty acid metabolism during exhaustive exercise in GH-deficient adults. J Clin Endocrinol Metab. 2003;88(4):1792–7.

    Article  PubMed  CAS  Google Scholar 

  81. McMillan CV, Bradley C, Gibney J, Healy ML, Russell-Jones DL, Sonksen PH. Psychological effects of withdrawal of growth hormone therapy from adults with growth hormone deficiency. Clin Endocrinol (Oxf). 2003;59(4):467–75.

    Article  CAS  Google Scholar 

  82. Kann P, Piepkorn B, Schehler B, et al. Effect of long-term treatment with GH on bone metabolism, bone mineral density and bone elasticity in GH-deficient adults. Clin Endocrinol (Oxf). 1998;48(5):561–8.

    Article  CAS  Google Scholar 

  83. al-Shoumer KA, Gray R, Anyaoku V, et al. Effects of four years’ treatment with biosynthetic human growth hormone (GH) on glucose homeostasis, insulin secretion and lipid metabolism in GH-deficient adults. Clin Endocrinol (Oxf). 1998;48(6):795–802.

    Article  CAS  Google Scholar 

  84. Valimaki MJ, Salmela PI, Salmi J, et al. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults. Eur J Endocrinol. 1999;140(6):545–54.

    Article  PubMed  CAS  Google Scholar 

  85. Drake WM, Rodriguez-Arnao J, Weaver JU, et al. The influence of gender on the short and long-term effects of growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults: a 5-year study. Clin Endocrinol (Oxf). 2001;54(4):525–32.

    Article  CAS  Google Scholar 

  86. Gilchrist FJ et al. The effect of long-term untreated growth hormone deficiency (GHD) and 9 years of GH replacement on the quality of life (QoL) of GH-deficient adults. Clin Endocrinol (Oxf). 2002;57:363–70.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Endocrinology and Diabetes, Adelaide and Meath Hospital, Dublin, Ireland

    Anne McGowan

  2. Department of Endocrinology and Diabetes, Adelaide and Meath Hospital, Tallaght, Dublin 24, Ireland

    James Gibney

Authors
  1. Anne McGowan
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. James Gibney
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to James Gibney .

Editor information

Editors and Affiliations

  1. Princess Alexandra Hospital &, The University of Queensland, Centres for Health Research, Ipswich Road Woolloongabba 199, Brisbane, 4102, Queensland, Australia

    Ken Ho

Rights and permissions

Reprints and permissions

Copyright information

© 2011 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

McGowan, A., Gibney, J. (2011). Issues in Long-Term Management of Adults with Growth Hormone Deficiency. In: Ho, K. (eds) Growth Hormone Related Diseases and Therapy. Contemporary Endocrinology. Humana Press. https://doi.org/10.1007/978-1-60761-317-6_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-317-6_11

  • Published:

  • Publisher Name: Humana Press

  • Print ISBN: 978-1-60761-316-9

  • Online ISBN: 978-1-60761-317-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation